How many stocks does RTW INVESTMENTS, LP own?

As of Q4 2025, RTW INVESTMENTS, LP holds 91 positions in their 13F portfolio.

What is RTW INVESTMENTS, LP's largest holding?

MDGL at 11.6% of portfolio, worth $1.2B.

What is RTW INVESTMENTS, LP's total portfolio value?

$10B as of Q4 2025, tracked across 91 holdings.

Is RTW INVESTMENTS, LP a hedge fund?

RTW INVESTMENTS, LP is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does RTW INVESTMENTS, LP report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has RTW INVESTMENTS, LP's portfolio changed in Q4 2025?

View RTW INVESTMENTS, LP's latest portfolio changes, new positions, and exits for Q4 2025 on HoldingsIntel.

What is RTW INVESTMENTS, LP's investment strategy?

RTW INVESTMENTS, LP is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

RTW INVESTMENTS, LP Holdings Q4 2025 - Portfolio & Conviction Scores | HoldingsIntel

RTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q4 2025

Below Average(2.0 / 5.0)

$10B

AUM

Positions

New

Q4 2025

Filing Period

Quarterly Portfolio Change

SEC EDGAR SourceSEC Filings

RTW INVESTMENTS, LP manages $10B across 91 positions as of Q4 2025. Top holdings: MDGL (11.6%), INSM (8.4%), PTCT (5.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.

Q4 2025 Summary

Active quarter - 29 new positions, 12 exits, 20 increased. Top move: INSM (INCREASED, conviction 88). Portfolio: $10.0B across 91 positions.

Portfolio Allocation

Top holdings by portfolio weight

MDGL11.63%

INSM8.44%

PTCT5.89%

ARGX5.67%

PTGX4.43%

NTRA3.44%

RDNT2.81%

TARS2.74%

COGT2.70%

PEN2.70%

Other2.10%

Similar Funds

Funds with similar investing DNA

AXIOM INVESTORS LLC /DE

$11.4B

SRS Investment Management, LLC

$9.5B

+3 more

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

NTRA26Q held

NATERA INC

Avg $42.13 · $247.4M est. P&L

Est. P&L

+391.45%

ERAS1Q held

ERASCA INC

Avg $3.54 · $1.5M est. P&L

Est. P&L

+298.31%

RAPT5Q held

RAPT THERAPEUTICS INC

Avg $15.04 · $70.4M est. P&L

Est. P&L

+285.80%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings10 of 91

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
MDGL MADRIGAL PHARMACEUTICALS INC	2M	$1.2B	11.6%	—	$265.36	+60.48%	11 qtrssince 2023-Q2	Unchanged 0
INSM INSMED INC	4.8M	$842.9M	8.4%	—	$92.19	+59.45%	11 qtrssince 2023-Q2	Increased 88
PTCT PTC THERAPEUTICS INC	7.7M	$588.4M	5.9%	—	$43.73	+47.24%	28 qtrssince 2019-Q1	Unchanged 0
ARGXADR ARGENX SE SPONSORED ADR	673,497	$566.4M	5.7%	—	$355.08	+110.86%	28 qtrssince 2019-Q1	Unchanged 0
PTGX PROTAGONIST THERAPEUTICS INC	5.1M	$441.9M	4.4%	—	$24.36	+274.87%	26 qtrssince 2019-Q3	Decreased 0
NTRA NATERA INC	1.5M	$343.6M	3.4%	—	$42.13	+391.45%	26 qtrssince 2019-Q3	Decreased 0
RDNT RADNET INC	3.9M	$281M	2.8%	—	$55.94	+29.74%	9 qtrssince 2023-Q4	Increased 70
TARS TARSUS PHARMACEUTICALS INC	3.3M	$273.1M	2.7%	—	$36.05	+112.37%	21 qtrssince 2020-Q4	Increased 56
COGT COGENT BIOSCIENCES INC	7.6M	$269.7M	2.7%	—	$26.62	+39.89%	2 qtrssince 2025-Q3	Increased 85
PEN PENUMBRA INC	866,499	$269.4M	2.7%	—	$249.62	+36.27%	18 qtrssince 2021-Q3	Unchanged 0
Showing 10 of 91 results.81 more with Pro.PROUpgrade to see all →